>FDA Approves Johnson & Johnson Nasal Spray To Treat Depression
(New Brunswick, NJ) -- The FDA has approved a Johnson & Johnson nasal spray to treat major depression. That makes the spray, called Spravato, the first-ever stand-alone therapy for treating major depressive disorder that fails to improve with standard drug regimens. The FDA green light means Spravato, which has been used since 2019 along with an oral medication, can now be used by itself. Health experts say about a third of the 21-million U.S. adults who suffer from treatment-resistant major depression aren't getting relief from symptoms which can include persistent sadness, insomnia, lack of energy and suicidal ideations.